Title |
Pharmacokinetics of L-Carnitine
|
---|---|
Published in |
Clinical Pharmacokinetics, September 2012
|
DOI | 10.2165/00003088-200342110-00002 |
Pubmed ID | |
Authors |
Allan M. Evans, Gianfranco Fornasini |
Abstract |
L-Carnitine is a naturally occurring compound that facilitates the transport of fatty acids into mitochondria for beta-oxidation. Exogenous L-carnitine is used clinically for the treatment of carnitine deficiency disorders and a range of other conditions. In humans, the endogenous carnitine pool, which comprises free L-carnitine and a range of short-, medium- and long-chain esters, is maintained by absorption of L-carnitine from dietary sources, biosynthesis within the body and extensive renal tubular reabsorption from glomerular filtrate. In addition, carrier-mediated transport ensures high tissue-to-plasma concentration ratios in tissues that depend critically on fatty acid oxidation. The absorption of L-carnitine after oral administration occurs partly via carrier-mediated transport and partly by passive diffusion. After oral doses of 1-6g, the absolute bioavailability is 5-18%. In contrast, the bioavailability of dietary L-carnitine may be as high as 75%. Therefore, pharmacological or supplemental doses of L-carnitine are absorbed less efficiently than the relatively smaller amounts present within a normal diet.L-Carnitine and its short-chain esters do not bind to plasma proteins and, although blood cells contain L-carnitine, the rate of distribution between erythrocytes and plasma is extremely slow in whole blood. After intravenous administration, the initial distribution volume of L-carnitine is typically about 0.2-0.3 L/kg, which corresponds to extracellular fluid volume. There are at least three distinct pharmacokinetic compartments for L-carnitine, with the slowest equilibrating pool comprising skeletal and cardiac muscle.L-Carnitine is eliminated from the body mainly via urinary excretion. Under baseline conditions, the renal clearance of L-carnitine (1-3 mL/min) is substantially less than glomerular filtration rate (GFR), indicating extensive (98-99%) tubular reabsorption. The threshold concentration for tubular reabsorption (above which the fractional reabsorption begins to decline) is about 40-60 micromol/L, which is similar to the endogenous plasma L-carnitine level. Therefore, the renal clearance of L-carnitine increases after exogenous administration, approaching GFR after high intravenous doses. Patients with primary carnitine deficiency display alterations in the renal handling of L-carnitine and/or the transport of the compound into muscle tissue. Similarly, many forms of secondary carnitine deficiency, including some drug-induced disorders, arise from impaired renal tubular reabsorption. Patients with end-stage renal disease undergoing dialysis can develop a secondary carnitine deficiency due to the unrestricted loss of L-carnitine through the dialyser, and L-carnitine has been used for treatment of some patients during long-term haemodialysis. Recent studies have started to shed light on the pharmacokinetics of L-carnitine when used in haemodialysis patients. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Japan | 2 | 1% |
United Kingdom | 1 | <1% |
Italy | 1 | <1% |
Mexico | 1 | <1% |
United States | 1 | <1% |
Unknown | 149 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 24 | 15% |
Student > Ph. D. Student | 18 | 12% |
Student > Bachelor | 17 | 11% |
Student > Master | 15 | 10% |
Professor | 9 | 6% |
Other | 29 | 19% |
Unknown | 43 | 28% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 28 | 18% |
Medicine and Dentistry | 20 | 13% |
Biochemistry, Genetics and Molecular Biology | 17 | 11% |
Pharmacology, Toxicology and Pharmaceutical Science | 16 | 10% |
Chemistry | 5 | 3% |
Other | 20 | 13% |
Unknown | 49 | 32% |